Chongqing Huapont Pharmaceutical is an API manufacturer based in China. It holds 17 active US drug master files across a filed portfolio of 15 molecules.
| Molecule | Regulators | Docs |
|---|---|---|
| Bendamustine | US FDA | 2 |
| Isotretinoin | US FDA | 2 |
| Acitretin | US FDA | 1 |
| Acrivastine | US FDA | 1 |
| Dapsone | US FDA | 1 |
| Dimethyl Fumarate | US FDA | 1 |
| Fluticasone Propionate | US FDA | 1 |
| Levocetirizine | US FDA | 1 |
| Linezolid | US FDA | 1 |
| Moxifloxacin | US FDA | 1 |
| Naftifine | US FDA | 1 |
| Paricalcitol | US FDA | 1 |
| Roflumilast | US FDA | 1 |
| Ruxolitinib | US FDA | 1 |
| Tretinoin | US FDA | 1 |
Also appears on these molecule pages
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. Chongqing Huapont Pharmaceutical comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.